

Cardiovascular Safety Results of INP104 (POD-DHE) from the STOP 301 Phase 3 Study

Karen Craig, PhD^{1*}; John Hoekman, PhD¹; Maria Jeleva, PhD¹; Jasna Hocevar-Trnka, MD¹; Sheena Aurora, MD¹; Stephen Shrewsbury, MB ChB¹

¹Impel NeuroPharma, Seattle, WA, USA

*Presenting author

Introduction

- Dihydroergotamine (DHE) has long been used and recommended for the treatment of migraine due to its high response rate and sustained efficacy¹
- However, despite over 70 years of clinical experience, DHE product labels warn of potential cardiovascular (CV) and peripheral ischemic events^{1,2}
- INP104 is a novel, investigational drug-device combination product that targets delivery of DHE mesylate to the upper nasal cavity using a gas-propelled Precision Olfactory Delivery (POD[®]) device, version I1231.3
- A Phase 1 study (STOP 101) found INP104 to be well tolerated and readily absorbed, showing ~1/10 of the C_{max} of intravenous (IV) DHE mesylate, yet displaying IV-like plasma levels from 20 minutes onwards⁴
- Phase 1 data showed significant blood pressure increases with IV DHE mesylate, but not with INP104, and no electrocardiogram (ECG) changes were observed⁵
- STOP 301 was a pivotal Phase 3 safety study on the use of INP104 for the acute treatment of migraine over 24 and 52 weeks

Objective

- To report the cardiovascular results of INP104 from the STOP 301 study

Methods

Study Design

- This was a pivotal Phase 3, interventional, open-label, single-group assignment study, assessing the safety, tolerability, exploratory efficacy, and patient

acceptability of INP104 over long-term use (NCT03557333)

- The study comprised a 4-week screening period, a 24-week treatment period for all patients, a treatment extension to 52 weeks for a subset of the patients, and a 2-week post-treatment follow-up period for all patients
- Although the primary focus of this study was on nasal safety (integrity and function), CV effects (treatment-emergent adverse events [TEAEs], concomitant medication use, vital signs, and ECGs) were regularly collected and reviewed against preexisting conditions, concomitant medication use, and INP104 exposure

Study Patients and Treatment

- Patients were adult (18-65 years) males and females with a documented diagnosis of frequent migraine, defined as experiencing a minimum of 2 migraine attacks, with or without aura, each month not qualifying as chronic migraine during the previous 6 months per the *International Classification of Headache Disorders*, version 3 beta
- Patients were in general good health, with no significant medical history or clinical abnormalities at baseline
- Patients were excluded if they had a history of CV events or presented with significant risk factors for CV disease
 - Patients with a history of hypertension could enroll if hypertension was stable and well controlled on current therapies for >6 months, provided no other risks were present
- After an initial 4-week screening period, patients were provided with up to 3 doses/week of INP104 to

nasally self-administer (one dose is one spray to each nostril, delivering a total of 1.45 mg DHE mesylate) with all self-recognized migraine attacks over 24 weeks, with a subset over 52 weeks

- Dosing was limited to no more than 2 doses within a 24-hour period or 3 doses within a 7-day period

Study Assessments

- The primary endpoint was to assess the safety and tolerability of INP104, which included adverse event (AE) collection from the time of patient consent until the last study follow-up visit, nasal endoscopy, and olfactory function testing
- Secondary endpoints
 - Vital signs, including blood pressure, were collected every 4 weeks starting at the 4-week screening period
 - 12-lead ECGs were performed at the 4-week screening period, at baseline (Week 0), Week 24, and Week 52

Results

Patient Disposition and Baseline Characteristics

- 360 patients were screened and enrolled into the 24-week treatment period
 - 354 patients who received at least 1 dose of INP104 were defined as the 24-week full safety set (FSS)
- 262 patients completed the 24-week treatment period

Adverse Events

- No serious AEs were considered related to INP104 use

Cardiac TEAEs

- No patient experienced a cardiac-related TEAE over 24 weeks

Vascular TEAEs

- Over 24 weeks, 5 patients (1.4%) experienced vascular TEAEs (Table 1)
- 4 patients (1.1%) experienced (mild) hypertension
 - 2 patients (Patients 2 and 3) had ongoing hypertension at the start of the study for which they were receiving treatment
 - Worsening hypertension for Patient 2 was assessed as related to INP104; however, the event resolved with additional treatment after 116 days
 - Of the 4 hypertensive patients, 3 completed the study and 1 withdrew due to pregnancy
- 1 patient (0.3%) experienced a hematoma that was not related to INP104, but was sustained during a motorcycle accident

Blood Pressure and ECG

- Overall, minimal mean changes from baseline were observed for systolic and diastolic blood pressure and for median heart rate, aggregate PR interval, QRS duration, QT interval, QT corrected with Fridericia's formula (QTcF), and RR interval over 24 weeks (Table 2 and 3)
- No patient had an overall interpretation of an abnormal clinically significant ECG or experienced a TEAE associated with an abnormal ECG

Concomitant Medication Use

- INP104 overuse and use with triptans (contraindicated) did not lead to concerning TEAEs

Cardiovascular Safety Results of INP104 (POD-DHE) from the STOP 301 Phase 3 Study

Karen Craig, PhD^{1*}; John Hoekman, PhD¹; Maria Jeleva, PhD¹; Jasna Hocevar-Trnka, MD¹; Sheena Aurora, MD¹; Stephen Shrewsbury, MB ChB¹

¹Impel NeuroPharma, Seattle, WA, USA

*Presenting author

Table 1. Vascular TEAEs Overview (24-Week FSS, N=354)

Patient	Duration (Days)	INP104 Doses at TEAE Start	Related to INP104	Relevant Medical History	Relevant Prior Treatment
Hypertension (mild)					
1	Ongoing ^a	10	No	None	None
2 ^b	116	17	Yes	Hypertension	Hydrochlorothiazide/irbesartan
3 ^b	Ongoing ^a	6	No	Obesity, Hypertension	Amlodipine
4	Ongoing ^a	22	No	None	None
Hematoma					
5	Ongoing ^a	11	No	None	None

^aThe TEAE was ongoing as of last contact with patient.

^bVerbatim term was worsening hypertension.

FSS = full safety set; TEAE = treatment-emergent adverse event.

Table 2. Mean Systolic and Diastolic Blood Pressure (24-Week FSS, N=354)

Week	Systolic BP (mmHg, Mean ± SD)	Diastolic BP (mmHg, Mean ± SD)
Baseline ^a	118.1 ± 12.44	77.3 ± 9.67
4 ^b	117.6 ± 12.38	77.1 ± 8.99
8 ^b	117.9 ± 13.34	77.0 ± 9.38
12 ^b	116.9 ± 12.67	76.1 ± 9.25
16 ^b	118.2 ± 12.88	77.5 ± 9.17
20 ^b	117.4 ± 12.35	76.9 ± 8.69
24 ^b	117.0 ± 12.55	76.7 ± 8.96
26 (Follow-up)	116.8 ± 12.51	77.0 ± 8.72

^aBaseline is defined as the last non-missing observation prior to the date of patient's enrollment into the study on Day 0.

^bPost-baseline only includes data from patients who started the first INP104 on/before the visit evaluated.

BP = blood pressure; FSS = full safety set; SD = standard deviation.

Table 3. Mean ECG Parameters (24-Week FSS, N=354)

Parameter	Baseline ^a (Mean ± SD)	Week 24 ^b (Mean ± SD)	End of Period (24-wk Trt, Mean ± SD) ^{b,c}
Median Heart Rate (beats/min)	69.7 ± 11.27	69.4 ± 10.61	69.5 ± 10.54
PR Interval, Aggregate (msec)	154.9 ± 20.89	153.2 ± 21.80	153.1 ± 21.19
QRS Duration, Aggregate (msec)	88.6 ± 9.88	88.3 ± 10.76	88.8 ± 10.13
QT Interval, Aggregate (msec)	391.6 ± 28.08	392.1 ± 27.19	390.6 ± 27.12
QTcF Interval, Aggregate (msec)	410.9 ± 18.84	410.6 ± 19.58	409.6 ± 19.11
RR Interval, Aggregate (msec)	878.58 ± 144.11	877.90 ± 127.76	877.53 ± 129.98

^aBaseline is defined as the last non-missing observation prior to the date of patient's enrollment into the study on Day 0; ^bPost-baseline only includes data from patients who started the first IP on/before the visit evaluated; ^cEnd of period (24-wk Trt) is defined as the last assessment with non-missing value during the 24-wk treatment period. FSS = full safety set; IP = investigational product; min = minute; msec = millisecond; QTcF = QT interval corrected for heart rate with Fridericia's formula; SD = standard deviation; Trt = treatment; Wk = week.

Conclusion

- Although patients with active CV disease were excluded from the STOP 301 study, no significant AEs were noted in the peripheral or CV system even in patients with CV risk factors or concomitant triptan use
- INP104 displayed few treatment-related vascular events and no treatment-related cardiac events
- INP104 was well tolerated when taken as directed in the STOP 301 study

References

1. Silberstein SD, et al. *Headache*. 2020;60:40-57.
2. MIGRANAL® [package insert]. Bausch Health Companies, Inc; 2019.
3. Hoekman J, et al. *US Neurol*. 2020;16:25-31.
4. Shrewsbury SB, et al. *Headache*. 2019;59:394-409.
5. Craig K, et al. Poster presented at: *AAN Annual Meeting*. May 4-10, 2019.

Disclosures and Acknowledgments

All authors are full-time employees and stockholders of Impel NeuroPharma. This research was sponsored by Impel NeuroPharma. Editorial support was provided by IMPRINT Science and funded by Impel NeuroPharma. IMPEL, POD, and the IMPEL Logo are registered trademarks of Impel NeuroPharma.

